Gadgeel Shirish M, Ramalingam Suresh S, Kalemkerian Gregory P
Department of Hematology and Oncology, Wayne State University, Karmanos Cancer Institute, 4HWCRC, 4100 John R Street, Detroit, MI 48201, USA.
Radiol Clin North Am. 2012 Sep;50(5):961-74. doi: 10.1016/j.rcl.2012.06.003.
Lung cancer is a heterogenous disease with 2 main subtypes: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Early-stage NSCLC is managed primarily by surgical resection, with adjuvant chemotherapy for selected patients with stage IB, II, and III disease. Patients with locally advanced stage III NSCLC are usually treated with combined modality therapy. Advanced NSCLC remains an incurable disease. Further advances will rely on improvements in understanding of the molecular events driving the malignant phenotype and the development of novel, targeted therapeutic strategies.
肺癌是一种异质性疾病，主要有两种亚型：非小细胞肺癌（NSCLC）和小细胞肺癌（SCLC）。早期非小细胞肺癌主要通过手术切除进行治疗，对于IB期、II期和III期疾病的特定患者进行辅助化疗。局部晚期III期非小细胞肺癌患者通常采用综合治疗。晚期非小细胞肺癌仍然是一种无法治愈的疾病。进一步的进展将依赖于对驱动恶性表型的分子事件的理解的改善以及新型靶向治疗策略的开发。
